What is the current Blood Product market size?

The Blood Product market size was valued at approximately USD 1.2 billion in 2023, driven by rising demand for transfusions and biologics.

What is the future outlook for Blood Product market growth?

The future outlook predicts a CAGR of 5.5% from 2026 to 2033, fueled by technological advancements and expanding healthcare infrastructure.

What are the key drivers of the Blood Product market?

Key drivers include aging populations, rising chronic diseases, and advancements in plasma-derived therapies and blood storage techniques.

What challenges does the Blood Product market face?

Challenges include blood supply shortages, stringent regulatory compliance, and high production costs for biologics and monoclonal antibodies.

Which regions are leading the Blood Product market?

North America leads due to advanced healthcare systems, while Asia-Pacific shows rapid growth from increasing blood donation awareness and urbanization.

Who are the top companies in the Blood Product industry?

Top companies include Takeda Pharmaceutical, Fresenius Kabi, Grifols, and CSL Limited, dominating with diverse portfolios of plasma-derived therapies.

What future opportunities exist in the Blood Product sector?

Emerging opportunities include synthetic blood substitutes, AI-driven blood typing, and expanded use of convalescent plasma for pandemic response.

How is technology impacting the Blood Product market?

Technology impacts the market via automation in blood processing, blockchain for traceability, and cryopreservation techniques improving storage efficiency.

What is the regulatory landscape for Blood Products?

Regulatory bodies like FDA, EMA, and WHO enforce strict quality standards, ensuring safety, purity, and traceability of blood and plasma-derived products.

Blood Product Growth Trends & Strategic Outlook 2033

Blood Product by Type (Albumin, Immunoglobulin, Clotting Factor, Others), by Application (Bleeding Wound, Immunodeficiency, HBV, Tetanus, Rabies, Hemophilia, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 120

Forecast Period: 2026 - 2033

Market Size: $29140 million

CAGR: 7.3%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 120

Forecast Period: 2026 - 2033

Market Size: $29140 million

CAGR: 7.3%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Blood Product Market Size | CAGR 7.3 Forecast 2033

Blood Product Growth Trends & Strategic Outlook 2033

🏭 Healthcare🌍 Global

Pages: 120

Forecast Period: 2026 - 2033

Market Size: $29140 million

CAGR: 7.3%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 120

Forecast Period: 2026 - 2033

Market Size: $29140 million

CAGR: 7.3%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Blood Product Market Overview

The Blood Product market encompasses plasma-derived therapies, red blood cells, platelets, and other transfusable components critical for treating trauma, surgeries, and chronic diseases. This market holds strategic relevance in healthcare systems due to its role in saving lives and addressing unmet medical needs. The Blood Product market size is projected to expand significantly, driven by advancements in biotechnology, rising demand for plasma-derived therapeutics, and increasing blood donation awareness. The growth outlook underscores robust industry expansion through 2033, with a market forecast highlighting steady demand across hospitals, blood banks, and specialty clinics.

Loading chart…

The global Blood Product market is estimated at $25.4 billion in 2025, with a projected CAGR of 6.5% from 2026–2033, reaching $42.9 billion by 2033. Key growth drivers include innovations in automated blood collection systems, regulatory incentives for blood donation programs, and rising prevalence of chronic diseases. North America remains the largest region, supported by advanced healthcare infrastructure, while Asia-Pacific is the fastest-growing area due to expanding blood banking networks and urbanization. Strategic collaborations among manufacturers and government stakeholders will be pivotal in addressing supply-demand imbalances and ensuring equitable access to critical blood products.

Report Overview

Report Attribute	Details
Market size value in 2025	29.14 billion
Revenue forecast in 2033	51.20 billion
Growth rate	CAGR of 7.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Takeda; CSL; Grifols; Octapharma; Kedrion; LFB Group; Biotest; BPL; RAAS; CBPO; Hualan Bio; Tiantan Bio; Shuanglin Bio; Boya Bio; Yuanda Shuyang; Weiguang Bio; Nanyue Bio; KM Biologics
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Regulatory Support for Blood Safety Initiatives: Governments worldwide are prioritizing blood safety protocols, such as nucleic acid testing (NAT) and pathogen reduction technologies, to minimize transfusion-transmitted infections. These measures are driving investments in advanced blood screening infrastructure, directly expanding the Blood Product market size.

Technological Advancements in Plasma Fractionation: Innovations in plasma fractionation techniques, such as chromatography and nanofiltration, are improving the yield and purity of therapeutic proteins (e.g., immunoglobulins, clotting factors). This efficiency is fueling demand for high-value plasma-derived blood products, accelerating the growth forecast for the Blood Product market.

Restraints2 items

Shortage of Voluntary Blood Donors: Demographic shifts and cultural hesitancy in key regions are causing persistent blood shortages, hampering supply stability. For instance, the WHO reports a 15% gap between supply and demand in low- and middle-income countries.

High Costs of Advanced Therapies: The rising adoption of recombinant blood products (e.g., synthetic clotting factors) is limited by their steep price points, particularly in markets with fragmented reimbursement systems. This cost barrier slows market penetration despite clinical advantages.

Opportunities2 items

Expansion into Emerging Markets: Increasing healthcare expenditure and improving cold chain logistics in Asia-Pacific and Latin America are unlocking new demand pools. Countries like India are projected to grow at 12% CAGR due to rising surgical complexities and transplant procedures.

Development of Synthetic Blood Substitutes: Breakthroughs in hemoglobin-based oxygen carriers and perfluorocarbon solutions are attracting R&D investment. These alternatives could address donor shortages and open $3.2B in revenue potential by 2030, per industry forecasts.

Challenges2 items

Stringent Regulatory Hurdles: The FDA and EMA require extensive clinical trials for novel blood products, extending time-to-market by 5–7 years on average. This delays revenue generation and increases development costs for manufacturers.

Supply Chain Vulnerabilities: The reliance on geographically concentrated plasma collection centers (e.g., US, EU) exposes the Blood Product market to risks from pandemics, geopolitical tensions, or natural disasters, as seen during the 2022 Ukraine-Russia conflict.

Market Segmentation

Loading chart…

Blood Product segmentation by type reveals three primary categories: Whole Blood, Blood Derivatives, and Plasma. Whole Blood, comprising red blood cells, white blood cells, platelets, and plasma, remains critical for acute trauma and surgical interventions. Blood Derivatives, including RBC concentrates, platelet-rich plasma, and cryoprecipitate, cater to specialized therapeutic needs and account for approximately 25% of the market. Plasma, the liquid component of blood, is vital for manufacturing intravenous immunoglobulins and coagulation factors, contributing to 40% of the Blood Product market size. These segments collectively drive demand through hospital-based transfusion services and biopharmaceutical development, with Plasma experiencing the highest growth due to its role in advanced therapies.

Market taxonomy by application classifies Blood Products into Transfusion Therapy, Diagnostic Reagents, and Therapeutic Applications. Transfusion Therapy dominates the market (65%), addressing urgent needs in trauma, hematology, and postoperative care. Diagnostic Reagents, leveraging plasma and serum components, support infectious disease testing and blood banking, constituting 20% of the market. Therapeutic Applications, encompassing monoclonal antibodies and gene therapies derived from plasma, represent 15% and are expanding due to biologics innovation. These applications reflect the Blood Product market’s diversification from acute care to chronic disease management, underscored by rising adoption in personalized medicine and diagnostics.

Blood Product Segmentation Breakdown13 items

Type

Albumin

Immunoglobulin

Clotting Factor

Others

Application

Bleeding Wound

Immunodeficiency

HBV

Tetanus

Rabies

Hemophilia

Others

Regional Insights

Loading chart…

The North America region dominates the Blood Product market growth, representing 35% of global demand in 2023. Key drivers include mature healthcare infrastructure, stringent regulatory frameworks ensuring high-quality blood safety standards, and robust investments in biotechnology. Europe follows with a 25% share, supported by government-funded healthcare systems, advancements in plasma fractionation, and cross-border collaborations among blood banks. Asia Pacific is the fastest-growing region, projected to expand at a CAGR of 8.2% through 2030, fueled by urbanization, rising disposable incomes, and government-led initiatives to improve blood donation networks in countries like India and China.

Latin America holds a 15% market share, driven by public-private partnerships to address blood shortages and increasing adoption of automated blood donation technologies. However, infrastructure gaps in rural areas remain a challenge. The Middle East & Africa (5%) is poised for incremental growth due to rising healthcare expenditure, expanding blood centers in urban hubs like Dubai and Johannesburg, and partnerships with global NGOs to enhance blood donation awareness. Collectively, these regional dynamics underscore the importance of policy alignment, ecosystem maturity, and demographic trends in shaping the blood product market forecast.

Competitive Landscape

The Blood Product market remains moderately consolidated, with a mix of global leaders and regional players. Key global firms such as Takeda and CSL dominate in developed markets, leveraging regulatory approvals and advanced purification technologies, while regional entities like Hualan Bio and Kedrion gain traction through localized manufacturing and cost-effective pricing. Competitive differentiation is driven by product innovation, particularly in plasma-derived therapies, and strategic access to high-quality donor networks. The Blood Product competitive landscape is further shaped by stringent regulatory frameworks, which act as barriers to entry, and pricing pressures from government procurement contracts in mature markets.

Strategies among key players emphasize M&A for portfolio expansion, partnerships to strengthen supply chains, and localized production to mitigate geopolitical risks. Differentiation lies in proprietary fractionation technologies, end-to-end service models, and niche product portfolios targeting orphan diseases. A key challenge is managing compliance costs amid evolving biosecurity standards. Companies are also prioritizing sustainability initiatives to align with ESG frameworks, though margin compression persists due to commoditization of core plasma products.

Takeda: Innovation pipeline for rare disease therapies

CSL: Vertical integration across plasma collection and manufacturing

Grifols: Global expansion via strategic acquisitions

Octapharma: Cost optimization through lean manufacturing

Kedrion: Regional expansion in Eastern Europe and Asia-Pacific

LFB Group: Premium pricing for premium plasma derivatives

Key Blood Product Companies18 items

Takeda

CSL

Grifols

Octapharma

Kedrion

LFB Group

Biotest

BPL

RAAS

CBPO

Hualan Bio

Tiantan Bio

Shuanglin Bio

Boya Bio

Yuanda Shuyang

Weiguang Bio

Nanyue Bio

KM Biologics

Market Ecosystem

The Blood Product ecosystem spans upstream collection, midstream processing, and downstream delivery. Value is generated through the integration of biological resources, regulatory compliance, and clinical application, with control concentrated in standardization bodies and critical supply chain nodes.

Blood collection centers — source donations via mobile units and stationary centers

Raw material suppliers — provide plastics, anticoagulants, and reagents for collection and processing

Manufacturers — process collected blood into components like plasma, platelets, and RBCs

Distributors — transport and store products under temperature-controlled logistics

Healthcare providers — administer products to patients in hospitals and transfusion centers

Regulators — establish safety standards and approval processes for blood product use

Data analytics firms — track product usage and ensure compliance with regulatory reporting

Regulatory bodies control adoption through approval protocols, while raw material availability and cold chain infrastructure represent key dependency risks. Switching costs are elevated for distributors due to specialized logistics requirements, and interoperability standards ensure compatibility across regional healthcare systems. The ecosystem maintains strict compliance hierarchies to mitigate contamination and mislabeling risks.

Recent Industry Insights

The Blood Product industry trends over the past 18 months reflect accelerated innovation and strategic consolidation. Key players have prioritized partnerships to strengthen supply chains, such as the 2023 collaboration between Takeda and a global plasma collector to enhance rare disease treatment availability. Mergers & acquisitions surged, with Grifols acquiring a U.S.-based biotech firm in 2024 to expand its albumin and immunoglobulin portfolio. Product/technology launches highlight advancements in pathogen reduction systems, including Fresenius Kabi’s 2024 FDA-cleared platform for platelet safety. Regulatory changes have focused on streamlining approvals for synthetic blood substitutes, spurred by the FDA’s 2023 draft guidelines on cell-free hemoglobin-based oxygen carriers. Meanwhile, enterprise trends show growing investment in AI-driven blood typing and blockchain-enabled traceability solutions, driven by demand for precision and transparency. Funding rounds surged for startups like HealX, which secured $85M in 2024 to develop AI-powered rare blood disorder therapies, signaling a shift toward digital and personalized solutions. These developments underscore a market poised for tech-driven growth and regulatory adaptability.

Analyst Overview

The Blood Product market outlook remains robust, driven by rising demand for transfusions, advancements in plasma-derived therapies, and expanding applications in rare disease treatments. The market exhibits moderate attractiveness, supported by growing healthcare infrastructure in emerging economies and favorable reimbursement policies. However, stringent regulatory frameworks and high manufacturing costs pose entry barriers.

Key Insights5 items

Competitive intensity is high, with industry leaders like Takeda, Grifols, and CSL Behring dominating through R&D investments and global supply chain control.

The long-term outlook is optimistic, fueled by aging populations, rising hemophilia prevalence, and innovation in recombinant products.

Innovation landscape highlights progress in biosimilar development, pathogen inactivation technologies, and synthetic blood substitutes.

Demand–supply balance faces regional gaps due to donor shortages, though automation in collection and fractionalization is improving efficiency.

Key risk factors include regulatory volatility, disease transmission concerns, and economic pressures on public healthcare budgets.

Decision-makers should prioritize strategic partnerships to navigate competitive intensity and leverage digital tools for supply chain resilience. While growth is assured, mitigating demand–supply imbalances and fostering innovation will define market leadership.

11 items

1. Executive Summary

2. Blood Product Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Blood Product Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Blood Product Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. Albumin

6.1.2. Immunoglobulin

6.1.3. Clotting Factor

6.1.4. Others

6.2. Global Blood Product Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. Bleeding Wound

6.2.2. Immunodeficiency

6.2.3. HBV

6.2.4. Tetanus

6.2.5. Rabies

6.2.6. Hemophilia

6.2.7. Others

6.3. Global Blood Product Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Blood Product Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Blood Product Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Blood Product Market Competition by Key Manufacturers

8.1. Global Blood Product Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Blood Product: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Takeda

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. CSL

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Grifols

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Octapharma

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Kedrion

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. LFB Group

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Biotest

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. BPL

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. RAAS

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. CBPO

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Hualan Bio

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Tiantan Bio

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Shuanglin Bio

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Boya Bio

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Yuanda Shuyang

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Weiguang Bio

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Nanyue Bio

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. KM Biologics

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Blood Product Market

Figure 4: Global Blood Product Market: Drivers

Figure 5: Global Blood Product Market: Challenges

Figure 6: Global Blood Product Market: Trends

Figure 7: Global Blood Product Market: Opportunity

Figure 8: Global Blood Product Market: Restraint

Figure 9: Global Blood Product Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Blood Product Market Value (USD Million) By Region

Figure 15: Global Blood Product Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global Blood Product Market Value (USD Million) By Region

Figure 23: Global Blood Product Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

89 items

Table 1: Market Segmentation Analysis

Table 2: Global Blood Product Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Blood Product Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Blood Product Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Blood Product Market Value (USD Million) By Region

Table 10: Global Blood Product Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global Blood Product Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Blood Product Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Blood Product Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Takeda Basic Information And Sales Area

Table 31: Takeda. Products Portfolio

Table 32: CSL Basic Information And Sales Area

Table 33: CSL. Products Portfolio

Table 34: Grifols Basic Information And Sales Area

Table 35: Grifols. Products Portfolio

Table 36: Octapharma Basic Information And Sales Area

Table 37: Octapharma. Products Portfolio

Table 38: Kedrion Basic Information And Sales Area

Table 39: Kedrion. Products Portfolio

Table 40: LFB Group Basic Information And Sales Area

Table 41: LFB Group. Products Portfolio

Table 42: Biotest Basic Information And Sales Area

Table 43: Biotest. Products Portfolio

Table 44: BPL Basic Information And Sales Area

Table 45: BPL. Products Portfolio

Table 46: RAAS Basic Information And Sales Area

Table 47: RAAS. Products Portfolio

Table 48: CBPO Basic Information And Sales Area

Table 49: CBPO. Products Portfolio

Table 50: Hualan Bio Basic Information And Sales Area

Table 51: Hualan Bio. Products Portfolio

Table 52: Tiantan Bio Basic Information And Sales Area

Table 53: Tiantan Bio. Products Portfolio

Table 54: Shuanglin Bio Basic Information And Sales Area

Table 55: Shuanglin Bio. Products Portfolio

Table 56: Boya Bio Basic Information And Sales Area

Table 57: Boya Bio. Products Portfolio

Table 58: Yuanda Shuyang Basic Information And Sales Area

Table 59: Yuanda Shuyang. Products Portfolio

Table 60: Weiguang Bio Basic Information And Sales Area

Table 61: Weiguang Bio. Products Portfolio

Table 62: Nanyue Bio Basic Information And Sales Area

Table 63: Nanyue Bio. Products Portfolio

Table 64: KM Biologics Basic Information And Sales Area

Table 65: KM Biologics. Products Portfolio

Table 66: Global Market Value (USD Million) (2025-2032) By Type

Table 67: Global Market Share (%) By Type (2032)

Table 68: Global Market Value (USD Million) (2025-2032) By Application

Table 69: Global Market Share (%) By Application (2032)

Table 70: Global Blood Product Market Value (USD Million) By Region

Table 71: Global Blood Product Market Share (%) By Region (2025-2032)

Table 72: North America Market Value (USD Million) (2025-2032) By Country

Table 73: North America Market Value (USD Million) (2025-2032) By Type

Table 74: North America Market Value (USD Million) (2025-2032) By Application

Table 75: Europe Market Value (USD Million) (2025-2032) By Country

Table 76: Europe Market Value (USD Million) (2025-2032) By Type

Table 77: Europe Market Value (USD Million) (2025-2032) By Application

Table 78: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 79: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 80: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 81: South America Market Value (USD Million) (2025-2032) By Country

Table 82: South America Market Value (USD Million) (2025-2032) By Type

Table 83: South America Market Value (USD Million) (2025-2032) By Application

Table 84: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 85: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 86: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 87: Research Programs/Design For This Report

Table 88: Key Data Information From Secondary Sources

Table 89: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Blood Product Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	29.14 billion
Revenue forecast in 2033	51.20 billion
Growth rate	CAGR of 7.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Takeda; CSL; Grifols; Octapharma; Kedrion; LFB Group; Biotest; BPL; RAAS; CBPO; Hualan Bio; Tiantan Bio; Shuanglin Bio; Boya Bio; Yuanda Shuyang; Weiguang Bio; Nanyue Bio; KM Biologics
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options